Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 15,608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Sensitization Study of ATx201 in Healthy Volunteers

NCT03375957
View directory record Official record
Conditions
Sensitivity, Contact
Interventions
ATx201, ATx201 Placebo Gel
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting Not applicable Interventional

A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer

NCT07447700
View directory record Official record
Conditions
Breast Cancer, Radiation Therapy Patient
Interventions
upper body massage
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

NCT00598507
View directory record Official record
Conditions
Melanoma
Interventions
ZK-EPO
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

BRCA Mutations in Latinas

NCT01251900
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Results available

Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

NCT00702507
View directory record Official record
Conditions
Diaper Rash
Interventions
0.25 % Miconazole Nitrate Ointment
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
Up to 15 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 30, 2026, 1:36 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 30, 2026, 1:36 PM EDT
Terminated Not applicable Interventional Results available

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

NCT01931709
View directory record Official record
Conditions
Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, dynamic contrast-enhanced magnetic resonance imaging, laboratory biomarker analysis
Radiation · Device · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting No phase listed Observational

CDH1-associated Blepharocheilodontic Syndrome Registry

NCT07133464
View directory record Official record
Conditions
Blepharocheilodontic Syndrome
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Green Tea Lozenges for the Management of Dry Mouth

NCT01647737
View directory record Official record
Conditions
Xerostomia, Sjogren Syndrome, Dry Mouth
Interventions
MighTeaFlow, Xylitol
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 4 Interventional

A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

NCT01327937
View directory record Official record
Conditions
Venous Ulcer
Interventions
Apligraf, Standard of Care Dressing Group
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 30, 2026, 1:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212
View directory record Official record
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
121
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

NCT05479812
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
WTX-124, pembrolizumab
Drug
Lead sponsor
Werewolf Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

NCT02581930
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

NCT02163694
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
56
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 30, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

NCT05379153
View directory record Official record
Conditions
Vaginal Atrophy, Breast Carcinoma
Interventions
Laser Therapy, Sham Intervention, Questionnaire Administration, Quality of Life Assessment
Device · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
22 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Des Moines, Iowa • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

NCT04947137
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tc99m tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Miami Lakes, Florida • Palmetto Bay, Florida • Kettering, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

NCT02452372
View directory record Official record
Conditions
Acute Intermittent Porphyria
Interventions
givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 30, 2026, 1:36 PM EDT
Withdrawn Phase 1 Interventional

PVSRIPO in Combination With Nivolumab in Melanoma

NCT04125719
View directory record Official record
Conditions
Melanoma
Interventions
PVSRIPO, Nivolumab
Biological · Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region

NCT04146467
View directory record Official record
Conditions
Lax Skin
Interventions
Renuvion APR Device
Device
Lead sponsor
Apyx Medical
Industry
Eligibility
35 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Montclair, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

RCT Comparing ESPB Solutions in Breast Surgery

NCT04603911
View directory record Official record
Conditions
Breast Cancer
Interventions
Liposomal bupivacaine, Bupivacaine, epinephrine, dexamethasone, and clonidine
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 30, 2026, 1:36 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

NCT05277571
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
UCB1381, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
16
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 1:36 PM EDT